Rapid Micro Biosystems pre-announces record Q4 rev $11.3M (+37% YoY); FY rev $33.6M (+20%)

RAPID MICRO BIOSYSTEMS, INC.

2025-FY EPS reported -$1.05 vs consensus -$0.23 ▼ miss (-362.6%)

Q4 2025 total revenue expected ~$11.3M, up ~37% YoY; record multi-system order from Top 20 biopharma customer.
Full year 2025 revenue expected ~$33.6M, up ~20% YoY; recurring revenue $17.8M (+15%).
Q4 placed 16 new Growth Direct systems, validated 3 customer systems; full year placed 28 and validated 18.
Cumulative installed base: 190 systems globally, 155 validated.
Company to announce complete FY2025 results and 2026 outlook later in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.